Treinta años después de la clonación de Dolly La clonación es algo cotidiano pero no es lo que se temía

Thirty years after the birth of Dolly the sheep, cloning has become routine, though not in the way many feared. On July 5, 1996, scientists in Scotland achieved what had long seemed impossible: they created a genetically identical animal from the body cell of an adult sheep. The breakthrough sparked global debate, with parliaments around the world and even the Vatican grappling with ethical implications. A central concern was whether human cloning would soon follow, given that a sheep could be cloned. Yet three decades later, human cloning remains science fiction, despite the widespread use of cloning techniques in research and industry. The process of cloning involves taking an egg cell from one animal, the “surrogate” mother, and removing its nucleus, which contains the genetic blueprint. Scientists then insert the nucleus from another animal’s cell, such as a skin cell, into the egg. This nucleus must be “reprogrammed” so it can function as a blueprint for developing an embryo. However, this step often fails. Many embryos stop developing early, leading to miscarriages or stillbirths. Dolly herself died prematurely, suffering from tumors and arthritis, highlighting the risks associated with the procedure. Despite these challenges, cloning has found applications in medicine. Researchers can now modify animal cells in laboratories and develop cloned animals with specific genetic traits. For example, pigs have been engineered to carry mutations linked to human diseases, allowing scientists to study these conditions more effectively. Such advancements underscore how cloning has evolved beyond its initial controversy, becoming a tool for medical innovation. Cloning is also increasingly commercialized. In countries like the United States, individuals can pay up to $50,000 to clone their beloved pets. This practice has gained traction among pet owners who wish to recreate lost companions. One notable case involves American football player Tom Brady, who cloned his late dog Lua through a private U.S. company. Today, Brady walks alongside a clone named Junie, a testament to the emotional and financial investment some people place in cloning technology. While cloning has become more accessible, it remains tightly regulated in many regions. Countries including Switzerland explicitly ban human cloning, reflecting ongoing ethical concerns. Dr. Rolf Zeller, an developmental biologist, notes that humans possess additional complexity compared to other animals, making cloning particularly risky. He explains that many cloned animals suffer from physical deformities or shortened lifespans, issues he believes should not be replicated in humans. The broader implications of cloning continue to spark discussion. While the fear of human cloning has not materialized, the technology's expansion raises new questions about ethics, regulation, and societal acceptance. As cloning becomes more integrated into scientific and commercial practices, the balance between innovation and responsibility remains a critical issue for policymakers and researchers alike.